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Pattern of cognitive deficits in 
severe COVID-19
The severe form of COVID-19 tends 
to be associated with neurological defi-
cits.1 2 Among patients with acute respi-
ratory distress syndrome (ARDS), who 
benefited from mechanical ventilation 
and were examined after discontinuation 
of sedation and neuromuscular blockade, 
69% presented agitation, 65% confusion, 
67% corticospinal tract signs and 33% 
dysexecutive syndrome.2
We describe here the pattern of cogni-
tive deficits in a series of 13 consecutive 
inpatients hospitalised in the Lausanne 
University Hospital, whom we exam-
ined during the post- critical acute stage 
of severe COVID-19 (table 1). Inclusion 
criteria were COVID-19 diagnosed by 
PCR and ARDS that required intubation 
and mechanical ventilation in intensive 
care unit (ICU). Exclusion criteria were 
prior psychiatric or neurological diseases, 
including neurocognitive impairment or 
dementia. At the time of testing, patients 
were no longer sedated and ICU delirium 
symptoms, which were present in seven 
patients, resolved in six of them (P5–P7, 
P10, P11, P13) or subsided to a great 
extent (P12).
The neuropsychological evaluation 
comprised two standardised test batteries. 
The Montreal Cognitive Assessment 
(MoCA; https://www. mocatest. org), 
which covers main cognitive functions, 
revealed normal cognitive performances 
in four patients (table 1; P1–P4), mild 
deficits in four (P5–P8) and moderate to 
severe deficits in five (P9–P13). MoCA 
subtests revealed selective cognitive 
pattern with lower performances in exec-
utive functions for patients with normal 
MoCA scores and more extensive cogni-
tive impairment in executive, memory, 
attentional and visuospatial functions, 
with relatively preserved orientation and 
language, for patients with mild to severe 
MoCA deficits.
The Frontal Assessment Battery (FAB; 
www. psychdb. com/ cognitive- testing/ fab) 
revealed executive dysfunction in eight 
patients (table 1; P6–P13). Among the 
FAB subtests, the most affected was lexical 
fluency, impaired in all patients except in 
one (with normal MoCA: P3).
Pearson (r) and Spearman (rho) 
correlation analyses were conducted. 
MoCA and FAB scores were correlated 
(r=0.88; p<0.001). Mental fatigue and 
cognitive slowness, assessed with obser-
vational scales, correlated with MoCA 
(respectively: rho=−0.67; p=0.012; 
rho=−0.74; p=0.004) and FAB scores 
(respectively: rho=−0.85; p<0.001; 
rho=−0.72; p=0.006). Age correlated 
with FAB (r=−0.591; p=0.033) but not 
with MoCA scores. There was no signif-
icant correlation between MoCA or 
FAB scores and the following measures: 
gender, length of ICU stay, duration of 
mechanical ventilation, delay between 
ICU discharge and cognitive assessment, 
mood and anxiety disturbances. Mood 
disturbance, assessed in self- report, was 
considerable (table 1; ≥5/10) in 38% of 
patients and 23% reported anxiety about 
breathing difficulties, fear of dying or 
reminiscences of intensive care. Seven 
patients presented ICU delirium (table 1); 
its occurrence was correlated with MoCA 
score (rho=−0.619; p=0.024) and cogni-
tive slowness (rho=0.585; p=0.036), but 
not with FAB, length of ICU stay, duration 
of mechanical ventilation, delay between 
ICU discharge and cognitive assessment, 
age, gender, mental fatigue, mood and 
anxiety disturbances.
Eleven patients had brain imaging. None 
of them sustained acute stroke or isch-
aemic damage; among the eight patients 
who had MRI- based morphometry, focal 
brain atrophy was, however, present in 
patients with normal (table 1; P1) or defi-
cient performance at MoCA (P10–P13) as 
it was absent in patients with normal (P3, 
P4) or deficient performance at MoCA 
(P7). Four patients had lumbar puncture, 
revealing enhanced proteinorachia (P3, 
P11, P13) and barrier index (P11, P13) or 
normal values (P12).
Two cognitive profiles characterise 
the post- critical acute phase of severe 
COVID-19: (1) normal score at MoCA, 
but tendency for lower performances in 
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P2 60s f 12 11 6 – N 28 15.6 2 2 2
P3 70s m 31 21 6 None N 26.9 15.6 0 2 3
P4 60s m 67 50 10 None N 26 14.4 1 2 1












P6 50s m 21 16 7 – Y 22 13.2 2 2 0
P7 50s m 21 17 5 None Y 21 14.4 2 2 3
P8 70s f 14 13 4 None N 19 9.6 1 2 2*












P10 60s m 27 19 2 rlFgm; lTgm; 
rlFwm; rlv; 
tv; fv
Y 16.8 2.4 3 3 3
P11 50s m 40 23 2 rlFgm; rlCgm Y 13 9.6 2 2 2
P12 70s m 25 25 7 rFgm; rlFwm; 
lPwm; rlOwm
Y 10 4.8 3 3 8
P13 70s f 24 19 6 rlFgm; rPgm; 
rlTgm; rlv; tv
Y 4 1.2 3 3 6
MEAN: 64.8 28.1 21.5 5.5   19.7 10.9   1.9 2.2 3.9
SD: 7.6 15.2 11.2 2.4   7.5 5.5   1.0 0.6 2.8
Patients were ranked from highest to lowest performing at MoCA test. Three patients had a CT scan, which was within normal range (P5, P8, P9); eight patients had an MRI- based morphometry, which was within normal range in three patients (P3, P4, P7) and showed signs of 
atrophy, in bold, in five other patients (P1, P10–P13). ICU delirium was rated N (no delirium) or Y (with delirium). Scores at MoCA and FAB: performance within normal limits is in italics, deficient in bold. For the MoCA, the maximum score is 30 and deficient score below 26 (see 
https://www.mocatest.org for details): four patients (P1–P4) had normal performances (score ≥26), four patients (P5–P8) had mild deficits (score between 25 and 18) and five patients (P9–P13) had moderate to severe deficits (score below 18). For the FAB, the maximum score is 18. 
The cut- off score of normal performance is determined by age and educational level (see www.psychdb.com/cognitive-testing/fab for details). The subtest environmental autonomy not having been evaluated because of sanitary requirements, we have extrapolated for the missing 
subtest by multiplying the FAB score by 1.2. For each MoCA subtest (At: attention, Ex: executive functions, La: language, Me: memory, Or: orientation, VS: visuospatial abilities) and FAB subtest (Co: conceptualisation, Fl: mental flexibility, Inh: inhibitory control, Int: sensitivity to 
interference, Pr: programming) means were calculated within three groups of patients: normal performance at MoCA score (mean P1–P4), mild deficits at MoCA score (mean P5–P8), moderate to severe deficits at MoCA score (mean P9–P13). Cognitive slowness and mental fatigue 
were rated on an observational scale of 3 (3 corresponding to a severe manifestation). Mood disturbance was rated on a self- assessment scale of 10 (10 corresponding to most affected) and anxiety with a yes/no question (yes=present*). Last two rows: mean and SD.
C, cingulate gyrus; f, female; F, frontal gyrus; FAB, Frontal Assessment Battery; fv, fourth ventricle; gm, grey matter; ICU, intensive care unit; l, left; lv, left ventricle; m, male; MoCA, Montreal Cognitive Assessment; O, occipital gyrus; P, parietal gyrus; r, right; rv, right ventricle; T, temporal 
gyrus; tv, third ventricle; wm, white matter.
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executive than in other cognitive functions; 
(2) mild to severe deficits at MoCA with 
extensive cognitive impairment in execu-
tive, memory, attentional and visuospatial 
functions, but relatively preserved orienta-
tion and language, executive dysfunction 
being confirmed by the FAB score. These 
cognitive profiles together with mood and 
anxiety disturbances, which we observed 
in the acute stage, in the absence of stroke, 
are reminiscent of those reported in the 
aftermath of ARDS of other aetiologies, 
where up to 70% of ARDS survivors had 
presented at hospital discharge cognitive 
deficits, affecting predominantly atten-
tion, mental processing speed, memory 
and executive functions,3–5 with a high 
prevalence of depression and anxiety.5
Furthermore, cognitive impairment in 
severe COVID-19, as in ARDS of other 
aetiologies,5 does not correlate with length 
of mechanical ventilation or length of ICU 
stay and thus severity of the acute illness. 
However, the occurrence of ICU delirium 
tends to be associated with poorer cogni-
tive performance.1
Structural damage, such as ischaemic or 
hypoxemic lesions of the hippocampus, 
basal ganglia or cerebellum lesions as 
well as brain atrophy (in particular 
hippocampal) or disruption of functional 
connectivity, which occur frequently in 
ARDS survivors,3 4 may contribute to 
cognitive dysfunction. In the context of 
COVID-19, stroke and perfusion abnor-
malities have been reported,1 2 but were 
excluded here in all 11 patients, who had 
brain imaging during the acute stage.
Prior brain atrophy may confer worse 
outcome as shown for the risk to develop 
delirium and cognitive disorders in ARDS 
of other aetiologies.3 4 Patchy grey and/or 
white matter atrophy was present in five 
patients (of the eight who had MRI), most 
likely reflecting a prior condition; it was 
associated with cognitive impairment in 
four patients. However, brain atrophy did 
not always induce cognitive impairment 
and conversely, cognitive impairment 
was also present without imaging abnor-
malities, as in previous non- COVID-19 
studies.4
Our sparse data on cerebrospinal fluid 
suggest that increased blood–brain barrier 
permeability may contribute to neurolog-
ical symptoms, as previously described for 
mild central nervous system inflammation 
in ICU patients.1
In conclusion, pattern of cognitive 
deficits, present during the acute stage in 
our 13 patients without history of cogni-
tive, psychiatric or neurological disor-
ders, is probably linked to critical illness 
as part of ARDS due to COVID-19, 
since it is very similar to those reported 
in ARDS of other aetiologies. Further 
investigations are needed to determine 
predictive factors and underlying neural 
mechanisms, and clarify with a long- 
term follow- up whether patients will 
completely recover.
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